Bioiberica to organize a joint healthcare workshop within the 1st SEMERGEN-SEFAC Congress
- Two consensus documents on osteoarthritis and appropriate use of SYSADOA products will be presented.
- All the information on medicines and products for joint healthcare will be at the attendees’ disposal at booth #1.
Bioiberica will be present at the 1st Medical and Pharmaceutical National Congress of the SEMERGEN-SEFAC with a workshop for all professionals specializing in joint healthcare and osteoarthritis scheduled for next Saturday, February 9th, at 9 am. Hall 5.
María Edelmira Córcoles Ferrándiz, community pharmacist and member of the pain management group of the SEFAC will be in charge of the workshop, entitled Joint healthcare, novelties in the pharmacologic treatment of osteoarthritis. The speakers will Dr. Sergio Giménez Basallote, community pharmacist Francesc Moranta Ribas, and Josep Vergés Milano, President of the Osteoarthritis Foundation International (OAFI).
This workshop will review the most noted updates in the pharmacological treatment of osteoarthritis, as well as the recommendations for the management of hand osteoarthritis recently published by EULAR (European League Against Rheumatism). In these new guidelines (the old ones were published back in 2007) EULAR give a series of overreaching principles and recommendations, both pharmacological and non pharmacological, based on the scientific evidence published to date.
Furthermore, the SEMERGEN-SEFAC-OAFI consensus document in osteoarthritis will be presented. This document highlights the key role of the community pharmacist to improve the OA patients’ quality of life by means of treatment adherence and pharmacist-therapeutic monitoring. This document is born out of the cooperation between two medical societies involved in osteoarthritis treatment (SEMERGEN, for primary care physicians and SEFAC, for community pharmacists) and OAFI, Osteoarthritis Foundation International.
The Osteoarthritis Foundation International will also present a consensus document on the proper use of SYSADOAs, specific medicines for the symptomatic treatment of osteoarthritis. This recommendation paper has been developed using the DELPHI method, a systematic and interactive predictive method, which is based on an expert panel to determine the best use of oral SYSADOA drugs (Chondroitin sulfate, glucosamine, CS+GL, diacerein) for the management of osteoarthritis in primary health care.
During the two days of the congress (8-9 February 2019) Bioiberica will be presenting at booth #1 of the exhibitors’ area its range of drugs for osteoarthritis and products for the improvement of joint healthcare.
